In a landmark public health decision, South Korea’s Mungyeong City has become the first region in the country to extend free HPV vaccination to 12-year-old boys, eliminating a long-standing gender disparity in cervical cancer prevention. This expansion, announced on May 6, 2026, follows growing international recognition that HPV vaccination benefits both males and females by preventing cancers linked to the virus, including oropharyngeal, anal, and penile cancers.

The move comes as South Korea prepares to include HPV vaccination in its national immunization program starting July 1, 2026, making it mandatory for all eligible adolescents. While the national program has historically focused on girls—who face higher risks of cervical cancer—local governments like Mungyeong are taking proactive steps to align with global best practices and reduce HPV-related cancers across all genders.

This development marks a significant evolution in South Korea’s approach to infectious disease prevention, reflecting both medical consensus and shifting societal attitudes toward gender-equitable healthcare. For parents and policymakers alike, the expansion raises essential questions about access, education, and the broader implications for public health strategies in Asia and beyond.

Why This Expansion Is a Public Health Milestone

Human papillomavirus (HPV) is the most common sexually transmitted infection globally, with over 14 million new infections annually in the U.S. Alone (CDC, 2025). While cervical cancer has been the primary focus of HPV vaccination campaigns, research increasingly highlights the virus’s role in other cancers:

• Oropharyngeal cancer: Linked to HPV strains 16 and 18, accounting for over 70% of cases in some regions.
• Anal cancer: Rates are rising among both men and women, with HPV detected in nearly 90% of cases.
• Penile cancer: Rare but preventable, with HPV implicated in 30–50% of cases.

By extending vaccination to boys, South Korea is not only addressing these lesser-discussed cancers but also leveraging a strategy known as “herd immunity.” Studies show that vaccinating boys can indirectly protect unvaccinated girls by reducing overall HPV transmission in the population.

The Science: Why HPV Vaccination for Boys Is Now a Global Standard

HPV vaccination has undergone a paradigm shift in the past decade. Initially developed to prevent cervical cancer in girls, the vaccine’s efficacy against other HPV-related cancers has led to its expansion in many countries. Key scientific milestones include:

• 2006: FDA approval of Gardasil, the first HPV vaccine, for girls aged 9–26.
• 2009: WHO recommendation for HPV vaccination as part of national immunization programs.
• 2014: Gardasil 9 approved, offering protection against nine HPV strains responsible for 90% of cervical cancers and 90% of genital warts.
• 2016: Australia became the first country to introduce HPV vaccination for boys nationwide.
• 2023: The U.S. Advisory Committee on Immunization Practices (ACIP) recommended routine HPV vaccination for boys aged 11–12.

South Korea’s decision aligns with this global trend. A 2025 study published in The Lancet estimated that vaccinating 80% of boys and girls could prevent over 4.5 million cases of HPV-related cancers worldwide by 2050.

Mungyeong City Leads the Way: How the Expansion Will Work

Mungyeong City’s decision to include 12-year-old boys in its HPV vaccination program is part of a broader strategy to strengthen youth health infrastructure. Here’s how the rollout will proceed:

• Eligibility: Boys born in 2014 (currently 12 years old) are now eligible for the two-dose series, administered six to twelve months apart.
• Coverage: The vaccination is fully funded by the national healthcare system, with no out-of-pocket costs for families.
• Distribution: Vaccinations will be available at local health centers, schools, and mobile clinics in collaboration with the city’s education and health departments.
• Education Campaign: Mungyeong City is partnering with schools and community organizations to raise awareness about HPV, its link to cancers, and the safety of the vaccine.
• Monitoring: The city will track vaccination rates and adverse event reports through its existing infectious disease surveillance system.

This initiative builds on Mungyeong’s reputation for innovative public health programs. In 2025, the city launched a similar expansion for hepatitis B vaccination, targeting both genders to reduce liver cancer risks.

Addressing Parent and Community Questions

As with any new public health initiative, questions and concerns have emerged. Here are answers based on verified sources:

1. Is the HPV vaccine safe for boys?

The HPV vaccine has undergone rigorous testing. A 2024 meta-analysis in Vaccine reviewed data from over 10 million doses administered globally, concluding that serious adverse events are rare and comparable to other adolescent vaccines. Common side effects include mild pain at the injection site and low-grade fever.

2. Why focus on 12-year-olds?

Vaccination before sexual debut maximizes effectiveness. The immune response is strongest when the vaccine is administered before HPV exposure. The World Health Organization recommends HPV vaccination at ages 9–14, a window when the immune system is particularly responsive.

3. How does this affect unvaccinated adults?

While the vaccine is most effective when given before HPV exposure, adults up to age 45 can still benefit. South Korea’s national program will continue offering catch-up vaccinations for older age groups, though at a higher cost (typically covered by private insurance).

4. Will this lead to increased sexual activity among teens?

No credible evidence supports this claim. A 2023 study in JAMA Pediatrics found that HPV vaccination does not influence sexual behavior in adolescents. The vaccine’s primary purpose is disease prevention, not behavioral modification.

5. What’s next for South Korea’s national program?

Starting July 1, 2026, HPV vaccination will become mandatory for all eligible adolescents under South Korea’s national immunization program. The Ministry of Health and Welfare is expected to release detailed guidelines on scheduling, distribution, and monitoring in the coming weeks.

South Korea in the Global HPV Vaccination Landscape

South Korea’s expansion places it among a growing number of countries adopting gender-inclusive HPV vaccination policies. Here’s how it compares to other nations:

Source: World Health Organization Global HPV Vaccination Coverage Data (2025) — who.int

Next Steps: What Parents and Policymakers Should Watch

The timeline for South Korea’s HPV vaccination expansion includes several critical milestones:

1. June 2026: Mungyeong City completes its initial vaccination campaign for 12-year-old boys, with plans to expand to other age groups if successful.
2. July 1, 2026: National mandatory HPV vaccination begins for all eligible adolescents (ages 12–13). Local health departments will issue detailed scheduling instructions.
3. August 2026: The Ministry of Health and Welfare is expected to release the first quarterly report on vaccination rates and adverse event monitoring.
4. 2027: Potential expansion of the program to include older age groups (up to age 26) for catch-up vaccinations.

Parents in Mungyeong should contact their local health center or school nurse for vaccination appointments. Those outside Mungyeong should monitor updates from the Ministry of Health and Welfare for regional rollout details.